Advertisement

Pharmaceutical Research

, Volume 28, Issue 5, pp 1121–1130 | Cite as

Development and In Vitro-In Vivo Evaluation of Polymeric Implants for Continuous Systemic Delivery of Curcumin

  • Shyam S. Bansal
  • Manicka V. Vadhanam
  • Ramesh C. Gupta
Research Paper

ABSTRACT

Purpose

The introduction of curcumin into clinics is hindered by its low water solubility and poor bioavailability. To overcome these limitations, we developed curcumin implants using poly (ε-caprolactone) as the polymeric matrix.

Methods

Implants were prepared by melt-extrusion method; in vitro drug release was optimized for effects of polymer composition, drug load, surface area and water-soluble additives. Implants were also tested under in vivo conditions for cumulative curcumin release, and liver concentration was correlated with its efficacy to modulate selected xenobiotic-metabolizing enzymes (CYP1A1 and GSTM).

Results

Drug release from implants followed biphasic release pattern with Higuchi kinetics and was proportional to the surface area of implants. Drug release increased proportionately from 2 to 10% (w/w) drug load, and incorporation of 10% (w/w) of water-soluble additives (F-68, PEG 8000 and cyclodextrin) did not significantly alter the drug release. In vivo drug release was found to be ∼1.8 times higher than in vitro release. Curcumin was detected at 60 ± 20 ng/g in the liver after four days of implantation and was almost constant (8–15 ng/g) for up to 35 days. This time-dependent drop in curcumin level was found to be due to induction of CYP1A1 and GSTM (μ) enzymes which led to increased metabolism of curcumin.

Conclusion

Our data showed that these implants were able to release curcumin for long duration and to modulate liver phase I and phase II enzymes, demonstrating curcumin’s biological efficacy delivered via this delivery system.

KEY WORDS

bioavailability chemoprevention controlled release curcumin implants 

ABBREVIATIONS

ACN

acetonitrile

BCS

bovine calf serum

CYP 1A1

cytochrome P450 1A1

DCM

dichloromethane

DSC

differential scanning calorimetry

ECF

extracellular fluid

FT-IR

Fourier transform infrared spectroscopy

GSTM

glutathione S-transferase (μ)

HPCD

2-hydroxyl propyl β-cyclodextrin

PBS

phosphate-buffered-saline

PCL

poly (ε-caprolactone)

PEG 8K

polyethylene glycol (molecular weight 8,000)

PXRD

powder X-ray diffraction

SEM

scanning electron microscopy

Notes

ACKNOWLEDGMENTS

This research work was supported from USPHS grants CA-118114, CA-125152, CA-90892, and from Agnes Brown Duggan Endowment. R.C.G. is Agnes Brown Duggan Chair in Oncological Research. Dr. Hina Kausar is acknowledged for her assistance in the western blot studies.

Supplementary material

11095_2011_375_MOESM1_ESM.ppt (558 kb)
Electronic supplementary Figures. (PPT 558 kb)

REFERENCES

  1. 1.
    Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem. 2010;17:190–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363–98.PubMedGoogle Scholar
  3. 3.
    Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol. 2008;76:1590–611.PubMedCrossRefGoogle Scholar
  4. 4.
    Aggarwaland BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41:40–59.CrossRefGoogle Scholar
  5. 5.
    Aggarwal BB. Apoptosis and nuclear factor-kappa B: a tale of association and dissociation. Biochem Pharmacol. 2000;60:1033–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999;27:486–94.PubMedGoogle Scholar
  7. 7.
    Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1, 7-bis-(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione) in the rat. Xenobiotica. 1978;8:761–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008;28:110–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895–900.PubMedGoogle Scholar
  10. 10.
    Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14:4491–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004;90:1011–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Shahani K, Swaminathan SK, Freeman D, Blum A, Ma L, Panyam J. Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention. Cancer Res. 2010;70:4443–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Ma Z, Haddadi A, Molavi O, Lavasanifar A, Lai R, Samuel J. Micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J Biomed Mater Res A. 2008;86:300–10.PubMedGoogle Scholar
  14. 14.
    Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol. 2008;32:1119–23.PubMedGoogle Scholar
  15. 15.
    Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37:223–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007;330:155–63.PubMedCrossRefGoogle Scholar
  17. 17.
    Jain JP, Modi S, Domb AJ, Kumar N. Role of polyanhydrides as localized drug carriers. J Control Release. 2005;103:541–63.PubMedCrossRefGoogle Scholar
  18. 18.
    Hafeman AE, Li B, Yoshii T, Zienkiewicz K, Davidson JM, Guelcher SA. Injectable biodegradable polyurethane scaffolds with release of platelet-derived growth factor for tissue repair and regeneration. Pharm Res. 2008;25:2387–99.PubMedCrossRefGoogle Scholar
  19. 19.
    Ghalanbor Z, Korber M, Bodmeier R. Improved lysozyme stability and release properties of poly(lactide-co-glycolide) implants prepared by hot-melt extrusion. Pharm Res. 2010;27:371–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Kumar Naraharisetti P, Yung Sheng Ong B, Wei Xie J, Kam Yiu Lee T, Wang CH, Sahinidis NV. In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma. Biomaterials. 2007;28:886–94.PubMedCrossRefGoogle Scholar
  21. 21.
    Saltzmanand WM, Fung LK. Polymeric implants for cancer chemotherapy. Adv Drug Deliv Rev. 1997;26:209–30.CrossRefGoogle Scholar
  22. 22.
    Dhanikulaand AB, Panchagnula R. Localized paclitaxel delivery. Int J Pharm. 1999;183:85–100.CrossRefGoogle Scholar
  23. 23.
    Dashand AK, Cudworth 2nd GC. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods. 1998;40:1–12.CrossRefGoogle Scholar
  24. 24.
    Li C, Cheng L, Zhang Y, Guo S, Wu W. Effects of implant diameter, drug loading and end-capping on praziquantel release from PCL implants. Int J Pharm. 2010;386:23–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Pitt CG, Jeffcoat AR, Zweidinger RA, Schindler A. Sustained drug delivery systems. I. The permeability of poly(epsilon-caprolactone), poly(DL-lactic acid), and their copolymers. J Biomed Mater Res. 1979;13:497–507.PubMedCrossRefGoogle Scholar
  26. 26.
    Woodruffand MA, Hutmacher DW. The return of a forgotten polymer—polycaprolactone in the 21st century. Progress in Polymer Science. In Press, Corrected Proof.Google Scholar
  27. 27.
    Quitschke WW. Differential solubility of curcuminoids in serum and albumin solutions: implications for analytical and therapeutic applications. BMC Biotechnol. 2008;8:84.PubMedCrossRefGoogle Scholar
  28. 28.
    Ravoori S, Vadhanam MV, Sahoo S, Srinivasan C, Gupta RC. Mammary tumor induction in ACI rats exposed to low levels of 17beta-estradiol. Int J Oncol. 2007;31:113–20.PubMedGoogle Scholar
  29. 29.
    Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76–85.PubMedCrossRefGoogle Scholar
  30. 30.
    Bansal SS, Kaushal AM, Bansal AK. Co-relationship of physical stability of amorphous dispersions with enthalpy relaxation. Pharmazie. 2008;63:812–4.PubMedGoogle Scholar
  31. 31.
    Lemmouchi Y, Schacht E, Lootens C. In vitro release of trypanocidal drugs from biodegradable implants based on poly([var epsilon]-caprolactone) and poly(-lactide). J Control Release. 1998;55:79–85.PubMedCrossRefGoogle Scholar
  32. 32.
    Rothen-Weinhold A, Besseghir K, Gurny R. Analysis of the influence of polymer characteristics and core loading on the in vivo release of a somatostatin analogue. Eur J Pharm Sci. 1997;5:303–13.CrossRefGoogle Scholar
  33. 33.
    Weinberg BD, Blanco E, Gao J. Polymer implants for intratumoral drug delivery and cancer therapy. J Pharm Sci. 2008;97:1681–702.PubMedCrossRefGoogle Scholar
  34. 34.
    Pitt CG, Gratzl MM, Jeffcoat AR, Zweidinger R, Schindler A. Sustained drug delivery systems II: factors affecting release rates from poly(epsilon-caprolactone) and related biodegradable polyesters. J Pharm Sci. 1979;68:1534–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Costaand P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–33.CrossRefGoogle Scholar
  36. 36.
    Rosenberg Rachel T, Siegel Steven P, Dan N. Effect of drug loading on the rate of nicotine release from poly(?-caprolactone) matrices. Polymer degradation and performance, vol. 1004. American Chemical Society; 2009. pp. 52–59.Google Scholar
  37. 37.
    Desai KG, Mallery SR, Schwendeman SP. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants. Eur J Pharm Biopharm. 2008;70:187–98.PubMedCrossRefGoogle Scholar
  38. 38.
    Kipp J, Rabinow B, Gokarn Y. Excipient selection and criteria for injectable dosage forms. Excipient development for pharmaceutical, biotechnology, and drug delivery systems, vol. null. Informa Healthcare, 2006.Google Scholar
  39. 39.
    Ma G, Song C, Sun H, Yang J, Leng X. A biodegradable levonorgestrel-releasing implant made of PCL/F68 compound as tested in rats and dogs. Contraception. 2006;74:141–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Zhang X, McAuley KB, Goosen MFA. Towards prediction of release profiles of antibiotics from coated poly(-lactide) cylinders. J Control Release. 1995;34:175–9.CrossRefGoogle Scholar
  41. 41.
    Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 2007;595:453–70.PubMedCrossRefGoogle Scholar
  42. 42.
    Goud VK, Polasa K, Krishnaswamy K. Effect of turmeric on xenobiotic metabolising enzymes. Plant Foods Hum Nutr. 1993;44:87–92.PubMedCrossRefGoogle Scholar
  43. 43.
    Safe S, Wang F, Porter W, Duan R, McDougal A. Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanisms. Toxicol Lett. 1998;102–103:343–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64:353–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Shyam S. Bansal
    • 1
    • 2
  • Manicka V. Vadhanam
    • 2
  • Ramesh C. Gupta
    • 1
    • 2
  1. 1.Department of Pharmacology and ToxicologyUniversity of LouisvilleLouisvilleUSA
  2. 2.James Graham Brown Cancer CenterUniversity of LouisvilleLouisvilleUSA

Personalised recommendations